Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Market Potential | Analysts project $10-$20 price targets, reflecting optimism about SGT-003's potential in the $2.5B-$3B DMD market and upcoming regulatory milestones |
Technological Edge | Delve into Solid's proprietary AAV-SLB101 capsid technology, offering enhanced muscle targeting and superior manufacturing capabilities as key differentiators |
Pipeline Expansion | Explore Solid's strategic move into Friedreich's Ataxia and CPVT, leveraging gene therapy expertise to address high unmet needs in rare genetic disorders |
DMD Gene Therapy | Solid Biosciences' SGT-003 shows promising early results for Duchenne muscular dystrophy, with potentially best-in-class microdystrophin expression and clean safety profile |
Metrics to compare | SLDB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLDBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −3.8x | −0.6x | |
PEG Ratio | −0.12 | 0.23 | 0.00 | |
Price / Book | 2.0x | 2.8x | 2.6x | |
Price / LTM Sales | - | 8.1x | 3.4x | |
Upside (Analyst Target) | 158.2% | 52.5% | 41.3% | |
Fair Value Upside | Unlock | 12.3% | 4.9% | Unlock |